Global pharma major Lupin Limited on Thursday announced the launch of Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe, after having received approval from the United States Food and Drug Administration (U.S. FDA).
Ganirelix Acetate Injection, 250 mcg/0.5 mL, Single-Dose Prefilled Syringe is a generic equivalent to the reference listed drug (RLD), Ganirelix Acetate Injection, 250 mcg/0.5 mL of Organon USA LLC.
It is indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian hyperstimulation.
Ganirelix Acetate Injection had estimated annual sales of USD 87 million in the U.S. (IQVIA MAT December 2023).
Read Next
